Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
Christopher R. Butler(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States)), David Riddell(Eli Lilly (United States)), Kimberly Lapham(Scripps Research Institute), Kevin Parris, Eric Benvenuti(Scripps Research Institute), Luis Martinez-Alsina(Pfizer (United States)), Christopher J. Helal(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Xinjun Hou(Pfizer (United States)), Lorraine F. Lanyon(Scripps Research Institute), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), F.F. Vajdos(University of Utah), Brian T. O’Neill(Pfizer (United States)), Mei‐Hui Hsu(Chang Gung University of Science and Technology), Eric F. Johnson(Scripps Research Institute), Gabriela Barreiro(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Cathleen Gonzales
Cited by 45
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351